Total Payments
$127,540
2024 Payments
$28,839
Companies
55
Transactions
1,369
Medicare Patients
6,257
Medicare Billing
$628,470
Payment Breakdown by Category
Other$91,873 (72.0%)
Food & Beverage$27,300 (21.4%)
Consulting$4,430 (3.5%)
Travel$3,028 (2.4%)
Education$908.30 (0.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $91,873 | 65 | 72.0% |
| Food and Beverage | $27,300 | 1,245 | 21.4% |
| Consulting Fee | $4,430 | 8 | 3.5% |
| Travel and Lodging | $3,028 | 36 | 2.4% |
| Education | $908.30 | 15 | 0.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $86,450 | 382 | $0 (2024) |
| Insmed, Inc. | $21,855 | 65 | $0 (2024) |
| GlaxoSmithKline, LLC. | $4,128 | 242 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $1,561 | 86 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $1,454 | 63 | $0 (2024) |
| Actelion Pharmaceuticals US, Inc. | $1,226 | 50 | $0 (2024) |
| GENZYME CORPORATION | $1,115 | 56 | $0 (2024) |
| Mylan Specialty L.P. | $1,042 | 27 | $0 (2024) |
| HARMONY BIOSCIENCES LLC | $986.08 | 29 | $0 (2024) |
| Genentech USA, Inc. | $951.86 | 59 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $28,839 | 190 | AstraZeneca Pharmaceuticals LP ($25,563) |
| 2023 | $13,406 | 184 | AstraZeneca Pharmaceuticals LP ($10,538) |
| 2022 | $9,278 | 154 | AstraZeneca Pharmaceuticals LP ($6,944) |
| 2021 | $20,438 | 161 | AstraZeneca Pharmaceuticals LP ($16,658) |
| 2020 | $14,655 | 165 | AstraZeneca Pharmaceuticals LP ($6,091) |
| 2019 | $18,241 | 192 | Insmed, Inc. ($14,137) |
| 2018 | $11,831 | 160 | AstraZeneca Pharmaceuticals LP ($9,942) |
| 2017 | $10,852 | 163 | AstraZeneca Pharmaceuticals LP ($8,809) |
All Payment Transactions
1,369 individual payment records from CMS Open Payments — Page 1 of 55
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/13/2024 | Philips North America LLC | (AK6) Vest Therapy (Device) | Food and Beverage | Cash or cash equivalent | $16.11 | General |
| Category: Medical Device | ||||||
| 12/12/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,800.00 | General |
| Category: Respiratory | ||||||
| 12/11/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $28.12 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/11/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $19.61 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
| 12/10/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $101.56 | General |
| Category: Respiratory | ||||||
| 12/10/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Travel and Lodging | In-kind items and services | $55.20 | General |
| Category: Respiratory | ||||||
| 12/05/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug), UPTRAVI | Food and Beverage | In-kind items and services | $28.41 | General |
| Category: Cardiology | ||||||
| 12/05/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $24.47 | General |
| Category: Oncology | ||||||
| 12/04/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $23.19 | General |
| Category: Respiratory | ||||||
| 12/03/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $18.28 | General |
| Category: Respiratory | ||||||
| 12/03/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $14.28 | General |
| Category: Respiratory | ||||||
| 12/01/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $17.63 | General |
| Category: Respiratory | ||||||
| 11/26/2024 | Electromed, Inc. | SMARTVEST (Device) | Food and Beverage | Cash or cash equivalent | $97.96 | General |
| Category: HFCWO | ||||||
| 11/25/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $27.28 | General |
| Category: Respiratory | ||||||
| 11/20/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $16.27 | General |
| Category: Respiratory | ||||||
| 11/19/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $25.52 | General |
| Category: RESPIRATORY | ||||||
| 11/14/2024 | HARMONY BIOSCIENCES LLC | WAKIX (Drug) | Education | Cash or cash equivalent | $54.99 | General |
| Category: Narcoplepsy | ||||||
| 11/13/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $20.18 | General |
| Category: Respiratory | ||||||
| 11/12/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,400.00 | General |
| Category: Respiratory | ||||||
| 11/11/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $19.09 | General |
| Category: IMMUNOLOGY | ||||||
| 11/11/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $13.64 | General |
| Category: Respiratory | ||||||
| 11/11/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $2.75 | General |
| Category: IMMUNOLOGY | ||||||
| 11/07/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $19.52 | General |
| Category: Immunology | ||||||
| 11/06/2024 | Actelion Pharmaceuticals US, Inc. | OPSUMIT (Drug), UPTRAVI | Food and Beverage | In-kind items and services | $28.79 | General |
| Category: Cardiology | ||||||
| 10/29/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $30.93 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 998 | 1,507 | $343,840 | $128,865 |
| 2022 | 13 | 1,343 | 1,950 | $425,015 | $143,274 |
| 2021 | 13 | 2,197 | 2,982 | $641,649 | $202,153 |
| 2020 | 10 | 1,719 | 2,468 | $516,660 | $154,178 |
Total Patients
6,257
Total Services
8,907
Medicare Billing
$628,470
Procedure Codes
53
All Medicare Procedures & Services
53 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 450 | 700 | $192,500 | $67,517 | 35.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 187 | 429 | $55,770 | $26,717 | 47.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 107 | 107 | $37,450 | $13,445 | 35.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 48 | 50 | $18,000 | $7,110 | 39.5% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 54 | 54 | $13,230 | $5,099 | 38.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 70 | 71 | $13,490 | $3,631 | 26.9% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 22 | 36 | $6,840 | $3,513 | 51.4% |
| 94726 | Test to determine lung volumes using sensors | Office | 2023 | 18 | 18 | $2,160 | $667.16 | 30.9% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2023 | 16 | 16 | $1,920 | $534.42 | 27.8% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 11 | 11 | $605.00 | $352.55 | 58.3% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2023 | 15 | 15 | $1,875 | $277.90 | 14.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 441 | 655 | $188,150 | $63,271 | 33.6% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 229 | 575 | $94,700 | $32,895 | 34.7% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 86 | 92 | $27,265 | $10,240 | 37.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 121 | 149 | $29,110 | $10,072 | 34.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 69 | 69 | $28,850 | $8,417 | 29.2% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2022 | 108 | 108 | $12,075 | $5,348 | 44.3% |
| 94726 | Test to determine lung volumes using sensors | Office | 2022 | 108 | 108 | $12,090 | $5,060 | 41.9% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2022 | 110 | 110 | $18,765 | $3,547 | 18.9% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 11 | 20 | $5,500 | $1,731 | 31.5% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 11 | 11 | $3,300 | $952.13 | 28.9% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 16 | 17 | $2,260 | $684.21 | 30.3% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 20 | 20 | $1,100 | $628.20 | 57.1% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 13 | 16 | $1,850 | $428.71 | 23.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 353 | 1,018 | $200,599 | $62,033 | 30.9% |
About Dr. Gary Aaronson, DO
Dr. Gary Aaronson, DO is a Pulmonary Disease healthcare provider based in Philadelphia, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/12/2006. The National Provider Identifier (NPI) number assigned to this provider is 1770672040.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gary Aaronson, DO has received a total of $127,540 in payments from pharmaceutical and medical device companies, with $28,839 received in 2024. These payments were reported across 1,369 transactions from 55 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($91,873).
As a Medicare-enrolled provider, Aaronson has provided services to 6,257 Medicare beneficiaries, totaling 8,907 services with total Medicare billing of $628,470. Data is available for 4 years (2020–2023), covering 53 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Location Philadelphia, PA
- Active Since 10/12/2006
- Last Updated 07/08/2007
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1770672040
Products in Payments
- BREZTRI (Drug) $40,725
- BEVESPI AEROSPHERE (Drug) $17,752
- AIRSUPRA (Drug) $16,818
- Arikayce (Drug) $11,296
- BREZTRI AEROSPHERE (Drug) $5,654
- SYMBICORT (Drug) $3,202
- DUPIXENT (Biological) $2,461
- TRELEGY ELLIPTA (Drug) $1,974
- FASENRA (Biological) $1,174
- NUCALA (Biological) $978.48
- Yupelri (Drug) $888.29
- Xolair (Biological) $820.62
- STIOLTO RESPIMAT (Drug) $699.08
- ACTHAR (Biological) $673.61
- Adempas (Drug) $612.01
- OPSUMIT (Drug) $562.71
- ANORO (Drug) $556.86
- WAKIX (Drug) $524.48
- GLASSIA (Biological) $497.66
- XYWAV (Drug) $493.90
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pulmonary Disease Doctors in Philadelphia
Gerard Criner, Md, MD
Pulmonary Disease — Payments: $945,674
Pulmonary Disease $945,674
Jeffrey Edelson, M.d, M.D
Pulmonary Disease — Payments: $437,125
Pulmonary Disease $437,125
Steven Geller, Do, DO
Pulmonary Disease — Payments: $251,222
Pulmonary Disease $251,222
Parth Rali, Md, MD
Pulmonary Disease — Payments: $232,570
Pulmonary Disease $232,570
Boyd Hehn, Md, MD
Pulmonary Disease — Payments: $139,719
Pulmonary Disease $139,719
Edward Schulman, Md, MD
Pulmonary Disease — Payments: $132,370
Pulmonary Disease $132,370